Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2000-04-04
2002-11-19
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S464000, C424S468000, C424S469000, C424S470000
Reexamination Certificate
active
06482434
ABSTRACT:
CROSS-REFERENCE TO RELATED APPLICATIONS
Not applicable.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable.
BACKGROUND OF THE INVENTION
The percentage of persons whose health is jeopardized by too much weight is increasing. Evidence suggests that body weight is multifactorial in origin, reflecting inherited, environmental, cultural, socioeconomic, and psychological conditions. Increasing evidence suggests that being overweight is not a simple problem of will power, as is sometimes implied, but is a complex disorder of appetite regulation and energy metabolism. Many persons have a chronic tendency for becoming overweight that needs lifelong attention. Strategies employed to lose weight include caloric restriction, exercise, behavior modification, drugs, or combinations thereof, with or without medial supervision. Some attempts may be successful in the short term, but often the weight lost is regained.. Efforts to lose weight voluntarily encompass a continuum of individuals including those of normal or low weight who wish to lose weight for cultural, social, or psychological reasons to severely overweight persons who suffer resulting adverse medical consequences.
The success of a weight loss program is highly variable. Psychological factors play a role both in the maintenance of weight and in the success of any weight loss program. Participants can reduce baseline depression and anxiety associated with a desire to reduce weight, but only if they successfully lose weight. Little is known about the emotional impact of lesser degrees of success or of failure, but it is assumed that improved self-esteem is instrumental in the overall success of the program. There is also increasing evidence that mildly to moderately overweight women who are dieting may be at risk for binge-eating without vomiting and purging.
An individual's response to a weight loss strategy is unpredictable. Success rates can be expected to vary according to initial weight, the length of the treatment period, the magnitude of weight loss desired, and the motivation for wanting to lose weight. The effectiveness of unsupervised efforts to lose weight is difficult to judge because of limited data on strategies, compliance, and follow-up. Surveys indicate that many overweight people have tried to lose weight on multiple occasions; because many of these persons presumably are using these unsupervised strategies, their long-term success rates may be low.
In general, successful programs are those based on realistic goals that involve a negative calorie balance (caloric deficit) leading to a slow, steady weight loss. Success requires a regimen that can be adhered to long enough to reach the goal. Developing new weight reduction practices that could lead to a lifetime of weight control is also important. Other attributes of successful programs involve preparing the person to deal with high-risk emotional and social situations, self-monitor progress, solve problems, reduce stress, and maintain continual professional contact. Barriers to success include lack of feelings of self-efficacy, failure to lose weight early, premature termination of diet modifications or exercise or both, and lack of social and professional support. Serious underlying social or psychological problems such as depression also can be barriers to success.
It would be useful to have a treatment that would attenuate the negative psychological and physical aspects of a weight control regimen.
BRIEF SUMMARY OF THE INVENTION
The present invention is summarized in that a method for reducing at least one adverse effect of a negative calorie balance in a human includes the steps of administering to the human an amount of conjugated linoleic acid (CLA) effective to reduce at least one negative effect selected from the group consisting of a skin rash, a gastrointestinal problem, a negative mood effect, and a cognitive or central nervous system (CNS) side effect.
It is an object of the present invention to decrease one or more adverse effects of a negative calorie balance in a human.
It is another object of the invention to facilitate weight loss in a human for whom the adverse effects of weight reduction brought about by negative calorie balance pose a significant impediment to successful weight reduction.
It is an advantage of the present invention that the method for reducing adverse effects is effective without regard to the means by which a negative calorie balance is achieved.
Other objects, advantages, and features of the invention will become apparent upon consideration of the following detailed description.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
Not applicable.
DETAILED DESCRIPTION OF THE INVENTION
A human can be subjected to a negative calorie balance in any of a number of ways. In its most basic form, the term “negative calorie balance” refers to a situation in which a human burns more calories than he or she takes in. A human can take in calories by, e.g., oral ingestion, by gastrointestinal feeding, or by intravenous delivery. Humans can achieve a negative calorie balance by, e.g., reducing food intake, either with or without pharmaceutical assistance, or by increasing calorie-burning activity.
As will become apparent from the working example, reductions in adverse effects were observed in a double-blind controlled study of subjects who received either conjugated linoleic acid (CLA) or a vegetable oil placebo. Subjects were asked to self-report any physiological changes noted during the course of treatment. As the data below demonstrate, CLA is shown to have a statistically significant effect on certain conditions, broadly characterized as reduced skin rash, gastrointestinal problems, reduced negative mood, and reduced cognitive/CNS side effects.
CLA can contain various isomers of conjugated linoleic acid (the structures of which are known to the art) or can be a preparation of a single isomer. Distinct isomers can have distinct effects on various body systems (see U.S. Pat. No. 6,020,378, incorporated herein by reference as if set forth herein in its entirety). Other recent issued US patents relating to use of CLA include U.S. Pat. Nos. 5,919,451; 5,914,346; and 5,855,917, each of which is incorporated herein by reference as if set forth herein in its entirety. The particular effects of individual isomers on the adverse effects of a weight loss regimen are not well characterized. CLA administered in the method can contain about 1% to 99% trans-10, cis-12 CLA and approximately 99% to 1% cis-9, trans-10 CLA. CLA can be administered as a dietary supplement or in food, as free fatty acids, or as active esters (e.g., triglycerides, diglycerides, or monoglycerides), as active salts thereof, or in any other biologically active form. The CLA can be administered by any route that results in delivery of biologically active material to the recipient, including, but not limited to, oral, intravenous or intramuscular administration. The CLA can be formulated with a carrier to form a composition for administration in the method. An effective CLA-containing composition for oral administration is Tonalin-90, which is a mixture of about 90% CLA isomers (approximately 43.5% trans-10, cis-12 CLA, 42% cis-9, trans-11 CLA, 2% trans-trans CLA isomers, and 1.5% other CLA isomers). On oral administration, an effective amount of CLA is between about 1 and 10 grams per day, preferably 2 to 5 grams per day, although greater or lesser amounts may also be effective. The effective amount can also depend upon the CLA isomer ratio in the administered composition.
REFERENCES:
patent: 4328243 (1982-05-01), Horrobin et al.
patent: 5430066 (1995-07-01), Cook et al.
patent: 5444054 (1995-08-01), Garleb et al.
patent: 5554646 (1996-09-01), Cook et al.
patent: 5585400 (1996-12-01), Cook et al.
patent: 5814663 (1998-09-01), Cook et al.
patent: 5856149 (1999-01-01), Pariza et al.
patent: 5919451 (1999-07-01), Cook et al.
patent: 6020378 (2000-02-01), Cook et al.
Beerthuis et al., “Synthesis of a Series of Polyunsaturated Fatty Acids, Their
Atkinson, Jr. Richard L.
Pariza Michael W.
Bennett Rachel M.
Page Thurman K.
Quarles & Brady LLP
Wisconsin Alumni Research Foundation
LandOfFree
Method for reducing adverse effects of a weight loss regimen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing adverse effects of a weight loss regimen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing adverse effects of a weight loss regimen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2932609